The TFN Complete Guide to Stem Cell Companies Part 1: Share prices above $50
Today's Financial News - Posted November 20, 2008
Baltimore — (TFN): Investors expect that the Obama Administration will re-institute federal funding for new embryonic stem cell lines. This might have a negligible short-term effect on biotech companies’ actual prospects… but large segments of the investing public have come to erroneously believe that stem cell research as a whole was prohibited during the Bush Administration.
The resumption of federal funding may trigger a rush to buy into companies even remotely associated with stem cell research.
What are those companies? TFN has compiled an almost complete list of publicly traded stem cell companies that will help you narrow down the field for candidates who may profit for the initial investment surge…
This is Part 1. Read the rest of this TFN Research Report:
- The TFN Complete Guide to Stem Cell Companies Part 2: Share prices between $10 and $50
- The TFN Complete Guide to Stem Cell Companies Part 3: Share prices between $1 and $10
- The TFN Complete Guide to Stem Cell Companies Part 4: Share prices under $1
Stocks are grouped by price range as of September 21, 2009. Within the price range, the companies are in order by stock symbol.
over $100
EpiStem Holdings Plc: LON:EHP
Market Cap: $23.08 million
EpiStem Holdings Plc commercializes epithelial stem cells in the areas of oncology, gastrointestinal diseases and dermatology. Epistem provides testing, biomarker services and therapy development for partner biotechnology and pharmaceutical drug companies.
Stock price: $320.00
http://www.epistem.co.uk/
$50-$100
Amgen Inc. (NASDAQ:AMGN)
Market Cap: $62.96 billion
Amgen Inc. develops, manufactures and markets human therapeutics using cellular and molecular biology. Its products are in the areas of supportive cancer care, nephrology, inflammation and oncology.
Stock price: $62.00
http://www.amgen.com/
Celgene Corporation (NASDAQ:CELG)
Market Cap: $25.51 billion
Celgene Corporation develops and commercializes therapies to treat cancer and immune-inflammatory-related diseases.
Stock price: $55.63
http://www.celgene.com/
Genzyme Corporation (NASDAQ:GENZ)
Market Cap: $15.43 billion
Genzyme Corporation operates in six units: Renal products that treat patients suffering from renal diseases, Therapeutics products to treat patients suffering from genetic diseases, Transplant products for the prevention and treatment of graft rejection in organ transplantation and other hematologic and autoimmune disorders, Biosurgery products that meet medical needs in orthopaedics and broader surgical areas, Genetics testing services for the oncology, prenatal and reproductive markets, and Oncology for the treatment of cancer.
Stock price: $57.08
http://www.genzyme.com
Johnson & Johnson (NYSE:JNJ)
Market Cap: $167.66 billion
Johnson & Johnson develops, manufactures and sells a range of products in the healthcare field. With more than 250 operating companies, the company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics.
Stock price: $60.84
http://www.jnj.com/
Millipore Corporation (NYSE:MIL)
Market Cap: $8.34 billion
Millipore Corporation provides products, services and solutions to academic, biotechnology, and pharmaceutical customers. The company is made up of two divisions, Bioscience to assist pharmaceutical and biotechnology companies develop and evaluate drugs, and Bioprocess to help them manufacture the drugs on a commercial scale once they are approved.
Stock price: $76.88
http://www.millipore.com
Next Article: The TFN Complete Guide to Stem Cell Companies Part 2: Share prices between $10 and $50
Be the first to leave a reply.
Your comments are welcome
Follow TFN via RSS or Twitter |
 |
 |
 |
Advertisement
Latest Headlines
- The Big Picture for Sinobiopharma, Inc. (SNBP)
- Beazer Homes USA, Inc. (BZH) and Hovnanian Enterprises, Inc. (HOV) up despite horrid housing news
- The FDA catalyst: 2010 moves in MannKind (MNKD), Roche Holding (RHHBY), Acorda Therapeutics (ACOR) show it still works!
- Steepest drop since Feb. 2009: Here we go again!
- Is the silver run over? Coeur d’Alene Mines (CDE), Silver Wheaton (SLW), Alto Group (ALTO), Hecla Mining (HL), Endeavour Silver (EXK) close down